Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
In this study, the investigators investigate beneficial effects of ipragliflozin, newly developted SGLT2 inhibitor, on reduction in visceral fat area and degree of fatty liver in subjects with T2DM when added to metformin and pioglitazone therapy.
Epistemonikos ID: b87e696ace84d63ea37d4e970f0c18d53d7681f2
First added on: Mar 26, 2024